Raymond James Financial Inc. purchased a new stake in Alignment Healthcare, Inc. (NASDAQ:ALHC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 157,273 shares of the company's stock, valued at approximately $1,769,000. Raymond James Financial Inc. owned 0.08% of Alignment Healthcare at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in ALHC. R Squared Ltd acquired a new stake in shares of Alignment Healthcare in the 4th quarter valued at $55,000. Ballentine Partners LLC acquired a new stake in Alignment Healthcare in the fourth quarter valued at about $121,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Alignment Healthcare in the third quarter valued at about $131,000. Aigen Investment Management LP acquired a new position in Alignment Healthcare during the fourth quarter worth about $129,000. Finally, Proficio Capital Partners LLC bought a new position in shares of Alignment Healthcare in the fourth quarter worth about $184,000. Institutional investors and hedge funds own 86.19% of the company's stock.
Alignment Healthcare Price Performance
ALHC traded up $0.66 on Thursday, reaching $18.51. The company had a trading volume of 2,665,025 shares, compared to its average volume of 1,527,317. Alignment Healthcare, Inc. has a 52-week low of $4.46 and a 52-week high of $18.97. The company has a market cap of $3.55 billion, a price-to-earnings ratio of -24.04 and a beta of 1.49. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.60 and a current ratio of 1.60. The business has a 50 day simple moving average of $15.50 and a 200 day simple moving average of $13.14.
Insider Buying and Selling
In other Alignment Healthcare news, CEO John E. Kao sold 90,000 shares of Alignment Healthcare stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $13.06, for a total transaction of $1,175,400.00. Following the completion of the sale, the chief executive officer now owns 2,273,100 shares of the company's stock, valued at $29,686,686. The trade was a 3.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $13.61, for a total transaction of $408,300.00. Following the transaction, the president now directly owns 1,606,097 shares in the company, valued at $21,858,980.17. This trade represents a 1.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,981,855 shares of company stock worth $30,590,612. Corporate insiders own 6.60% of the company's stock.
Analyst Ratings Changes
ALHC has been the topic of a number of recent research reports. Stifel Nicolaus lifted their price target on Alignment Healthcare from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, February 28th. JPMorgan Chase & Co. upped their price target on shares of Alignment Healthcare from $14.00 to $17.00 and gave the company a "neutral" rating in a research report on Thursday, March 6th. Barclays boosted their price objective on shares of Alignment Healthcare from $8.00 to $9.00 and gave the stock an "underweight" rating in a research note on Friday, February 28th. Bank of America raised their target price on Alignment Healthcare from $15.50 to $18.50 and gave the stock a "buy" rating in a research report on Tuesday, March 4th. Finally, Stephens reissued an "overweight" rating and issued a $17.00 price target on shares of Alignment Healthcare in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Alignment Healthcare presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.83.
View Our Latest Report on Alignment Healthcare
About Alignment Healthcare
(
Free Report)
Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
Read More
Before you consider Alignment Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alignment Healthcare wasn't on the list.
While Alignment Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
